Precision Neuroscience taps former Nevro leadership to spearhead the commercial rollout of its brain-computer interface platform following a successful $250 million Series D financing round.
Nevro is mentioned as the former company of Precision's new president, but no direct impact on Nevro's operations.
Precision Neuroscience has appointed former Nevro CEO Konstantinos Alataris as president and Katherine Neuenfeldt as senior vice president of commercial strategies. The appointments follow the company's recent $250 million Series D funding round, signaling a strategic shift toward the commercialization of its brain-computer interface technology.
The new leadership team is tasked with advancing the company's brain-computer interface technology toward commercialization, leveraging their experience in implantable medical devices.